NCT03106181.

Trial name or title	A comparison of cataract surgery alone and cataract surgery with iStent
Methods	Study design: parallel‐group RCT Unit of randomization: unclear Number randomized: not reported Unit of analysis: not reported Number analyzed: not reported Exclusions and losses to follow‐up: not reported Handling of missing data: not reported
Participants	Country: Australia Age: not reported Gender: not reported Inclusion criteria: age > 18 years diagnosis of mild‐to‐moderate OAG presence of cataract requiring surgery good understanding of both verbal and written English able to provide informed consent Exclusion criteria: recent intraocular surgery within last 3 months other ocular pathology affecting visionInability to complete the elements of the study, e.g. coma, hemodynamic instability, ventilator dependence, that could be of concern in the investigator's judgment non‐elective hospitalization within the past 60 days that could be of concern in the investigator's judgment medical illness that in the judgment of the investigator would jeopardize the safe completion of the study. Examples include cancer, chronic inflammatory disease, chronic liver insufficiency, epilepsy, thrombocytosis Diagnoses in participants: OAG
Interventions	Intervention 1: iStent inject Intervention 2: phacoemulsification Length of follow‐up: 2 years
Outcomes	Primary outcomes: IOP reduction up to 2 years Secondary outcomes: number of glaucoma medications; participant treatment satisfaction up to 2 years Safety outcomes: not reported
Starting date	10 April 2017
Contact information	Jennifer C Fan Gaskin, FRANZCO drjfan@gmail.com
Notes	Type of study: awaiting classification, described as "recruiting" on ClinicalTrials.gov Funding source: Glaukos Corporation, Laguna Hills, CA, USA provided funding/support Disclosures of interest: not reported Publication language: not reported Trial registration: NCT03106181